Drug Approval | May 29, 2024
Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Subscribe To Our Newsletter & Stay Updated
